Report on Guest Lecture by Prof. Pramil Tiwari, Professor of Pharmacy Practice & Head Pharm Management Department, NIPER, Mohali

Topic: Is the Pharmacist community ready for AI

Date: [2/12/2024]

Venue: [Auditorium]

The United Institute of Pharmacy, Prayagraj, had the privilege of hosting Prof. Pramil Tiwari, Professor of Pharmacy Practice & Head Pharm Management Department, NIPER, Mohali, for a guest lecture on the critical topic of "Is the Pharmacist community ready for AI". The session provided an in-depth exploration of the challenges and strategic approaches involved in the intricate process of bringing a drug to market.

Prof. Alok Mukerjee, Principal, UIP welcomed our guest speaker. Head of Department, Pharmacy and HOD of all branches were present. Our esteemed faculty members were also present. All the students of D. Pharmacy, B Pharmacy and M Pharmacy were also present. Prof. Tiwari, a renowned expert in the field, began by highlighting the multifaceted nature of drug development, encompassing preclinical and clinical stages. He emphasized the significant risks associated with safety, efficacy, regulatory compliance, and market acceptance, illustrating these points with real-world examples from his extensive experience.

Key points discussed during the lecture included:

Analyzing risks in preclinical and clinical trials, including unforeseen adverse effects and ethical considerations, how AI has impacting our lives, some examples of AI in real life, Navigating global regulatory requirements to ensure compliance and approval, How emerging technologies like AI and predictive analytics can minimize development risks.

The session was interactive, with students and faculty engaging Prof. Tiwari in discussions on the future of drug development and the evolving role of risk management.

The lecture concluded with a vote of thanks, acknowledging Prof. Tiwari for his invaluable insights and inspiring guidance with a momento. This session was instrumental in enriching the participants' understanding of the dynamic and challenging pharmaceutical landscape.







